Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Other financing activities (2019 - 2025)

Historic Other financing activities for Pulmonx (LUNG) over the last 5 years, with Q3 2025 value amounting to $23000.0.

  • Pulmonx's Other financing activities changed N/A to $23000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $76000.0, marking a year-over-year increase of 4339.62%. This contributed to the annual value of $53000.0 for FY2022, which is 2926.83% up from last year.
  • As of Q3 2025, Pulmonx's Other financing activities stood at $23000.0.
  • Pulmonx's 5-year Other financing activities high stood at $100000.0 for Q1 2021, and its period low was $11000.0 during Q2 2021.
  • Over the past 3 years, Pulmonx's median Other financing activities value was $38000.0 (recorded in 2022), while the average stood at $46750.0.
  • Over the last 5 years, Pulmonx's Other financing activities had its largest YoY gain of 7500.0% in 2021, and its largest YoY loss of 9946.65% in 2021.
  • Over the past 3 years, Pulmonx's Other financing activities (Quarter) stood at $11000.0 in 2021, then soared by 381.82% to $53000.0 in 2022, then plummeted by 56.6% to $23000.0 in 2025.
  • Its Other financing activities was $23000.0 in Q3 2025, compared to $53000.0 in Q4 2022 and $11000.0 in Q2 2021.